Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives

Cancer pharmacogenomics is an evolving landscape and has the potential to significantly impact cancer care and precision medicine. Harnessing and understanding the genetic code of both the patient (germline) and the tumor (somatic) provides the opportunity for personalized dose and therapy selection...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics and personalized medicine 2016-01, Vol.9, p.65-77
Main Author: Patel, Jai N
Format: Article
Language:English
Subjects:
Biomarkers
Breast cancer
Cancer
Cancer patients
Cancer therapies
Care and treatment
Chemotherapy
Colorectal cancer
Cytotoxicity
Deoxyribonucleic acid
Disease
DNA
Drugs
Electronic health records
FDA approval
Gene expression
Genomes
Genomics
Immunotherapy
Medical prognosis
Medical research
Medicine
Melanoma
Mutation
Oncology
Patients
Pharmacodynamics
Pharmacogenetics
Pharmacogenomics
Precision medicine
Review
Substance abuse treatment
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer pharmacogenomics is an evolving landscape and has the potential to significantly impact cancer care and precision medicine. Harnessing and understanding the genetic code of both the patient (germline) and the tumor (somatic) provides the opportunity for personalized dose and therapy selection for cancer patients. While germline DNA is useful in understanding the pharmacokinetic and pharmacodynamic disposition of a drug, somatic DNA is particularly useful in identifying drug targets and predicting drug response. Molecular profiling of somatic DNA has resulted in the current breadth of targeted therapies available, expanding the armamentarium to battle cancer. This review provides an update on cancer pharmacogenomics and genomics-based medicine, challenges in applying pharmacogenomics to the clinical setting, and patient perspectives on the use of pharmacogenomics to personalize cancer therapy.
ISSN:1178-7066
1178-7066
DOI:10.2147/PGPM.S62918